A detailed history of Abbot Financial Management, Inc. transactions in Dexcom Inc stock. As of the latest transaction made, Abbot Financial Management, Inc. holds 11,823 shares of DXCM stock, worth $901,740. This represents 0.41% of its overall portfolio holdings.

Number of Shares
11,823
Previous 7,449 58.72%
Holding current value
$901,740
Previous $844,000 6.16%
% of portfolio
0.41%
Previous 0.46%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 08, 2024

BUY
$64.0 - $116.06 $279,936 - $507,646
4,374 Added 58.72%
11,823 $792,000
Q2 2024

Aug 09, 2024

BUY
$110.31 - $140.45 $50,191 - $63,904
455 Added 6.51%
7,449 $844,000
Q1 2024

May 13, 2024

BUY
$114.22 - $140.1 $38,492 - $47,213
337 Added 5.06%
6,994 $970,000
Q4 2023

Feb 09, 2024

BUY
$75.49 - $124.16 $117,764 - $193,689
1,560 Added 30.61%
6,657 $826,000
Q3 2023

Nov 13, 2023

BUY
$86.06 - $137.93 $101,292 - $162,343
1,177 Added 30.03%
5,097 $475,000
Q2 2023

Aug 14, 2023

SELL
$112.47 - $130.98 $21,706 - $25,279
-193 Reduced 4.69%
3,920 $503,000
Q4 2022

Feb 09, 2023

BUY
$84.98 - $122.67 $2,124 - $3,066
25 Added 0.61%
4,113 $465,000
Q2 2022

Aug 09, 2022

BUY
$67.99 - $132.89 $215,188 - $420,596
3,165 Added 342.9%
4,088 $305,000
Q1 2022

May 12, 2022

BUY
$94.08 - $130.2 $8,090 - $11,197
86 Added 10.27%
923 $472,000
Q4 2021

Feb 15, 2022

BUY
$129.87 - $162.82 $1,688 - $2,116
13 Added 1.58%
837 $449,000
Q3 2021

Nov 04, 2021

SELL
$106.71 - $143.18 $30,519 - $40,949
-286 Reduced 25.77%
824 $451,000
Q2 2021

Aug 05, 2021

BUY
$80.99 - $107.93 $5,831 - $7,770
72 Added 6.94%
1,110 $474,000
Q1 2021

May 13, 2021

BUY
$84.79 - $104.74 $7,122 - $8,798
84 Added 8.81%
1,038 $373,000
Q4 2020

Feb 11, 2021

BUY
$78.0 - $104.5 $74,412 - $99,693
954 New
954 $353,000

Others Institutions Holding DXCM

About DEXCOM INC


  • Ticker DXCM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 386,257,984
  • Market Cap $29.5B
  • Description
  • DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM ...
More about DXCM
Track This Portfolio

Track Abbot Financial Management, Inc. Portfolio

Follow Abbot Financial Management, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Abbot Financial Management, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Abbot Financial Management, Inc. with notifications on news.